Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Trends Pharmacol Sci. 2014 Nov 5;35(12):664–674. doi: 10.1016/j.tips.2014.10.007

Figure 6.

Figure 6

Targeting virulence factor formation in S. aureus. A, Initial step in the metabolic pathways to the virulence factor staphyloxanthin and cholesterol/ergosterol are the same. B, The cholesterol-lowing drug lead BPH-652 inhibits CrtM and inhibits formation of the orange carotenoid virulence factor. C, Bacteria treated with BPH-652 are killed by whole blood (ROS from neutrophils, macrophages). D. Mice treated with BPH-652 control a S. aureus infection (bacteria CFUs reduced by 98%). Reprinted with permission from reference [76].